ESG
Cardinal Health sets new benchmark in sustainability
In an era where sustainability has become a corporate buzzword, Jane Crowe, Managing Director of Cardinal Health ANZ, is pushing for real action.
In this Health Industry Hub podcast, she dissected the government’s climate commitments, the medtech industry’s sustainability roadblocks, and why Australia is at the heart of Cardinal Health’s next big move.
Last August, Assistant Health Minister Ged Kearney established an advisory group to address the health impacts of climate change, following the release of the National Health and Climate Strategy. But has it driven meaningful change, or is it yet another government talkfest?
Cardinal Health is making a game-changing move: its first remanufacturing facility outside the U.S. will be in Newcastle. But why Australia, and why now?
As a key member of the MTAA Sustainability Forum, Crowe is on the frontline of medtech’s sustainability challenges. The industry’s carbon footprint is massive, but slashing emissions isn’t as straightforward as it sounds. Supply chain complexities, regulatory hurdles, and reporting challenges all play a role in slowing progress.
With an election looming, Crowe didn’t hold back on what she wants from policymakers. She outlined a vision for a more climate-conscious future – one where sustainability isn’t an afterthought but a core business imperative.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics

Philips remote monitoring cuts hospital costs and ICU time by 69%
An innovative remote patient monitoring model has significantly improved post-operative care for patients, cutting ICU hours by 69% and saving […]
MoreNews - MedTech & Diagnostics

VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
VB Spine has officially taken the reins of Stryker’s spinal implants business in Australia and New Zealand. The transition builds […]
MoreNews - Pharmaceuticals

New therapy PBS listed in advanced Parkinson’s disease
A new therapeutic option for advanced Parkinson’s disease, Vyalev (foslevodopa with foscarbidopa), is now listed on the Pharmaceutical Benefits Scheme […]
MoreNews - Pharmaceuticals

PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
From 1 August 2025, two new biosimilars – SteQeyma (ustekinumab) and Omlyclo (omalizumab) – have been listed on the Pharmaceutical […]
More